Chemotherapy Induced Nausea and Vomiting (CINV) Flashcards
What are the consequences of not controlling chemo N/V? (5)
- Medical complications: electrolyte imbalances, dehydration
- Poor quality of life
- Poor adherence
- Dose reductions; treatment delays
- Poor outcomes
What are the goals of controlling chemo N/V? (2)
- No emesis
- No (or mild) nausea
What are some general ways in which chemo N/V can be controlled? (5)
- No one drug or strategy will work for all patients
- Reassess efficacy prior to each cycle
- For maximal benefit, initiate anti-emetics prior to chemotherapy
- Much easier to prevent than to treat
- Scheduled anti-emetics versus PRNs
What are the 4 types of CINV?
- Acute
- Delayed
- Anticipatory
- Breakthrough
What is acute CINV? What neurotransmitter is involved? (2)
- Occurs within 24 hours of treatment
- Serotonin dependent – use 5HT3 receptor antagonists
What is delayed CINV? What neurotransmitter is involved? (2)
- Occurs 24 to 120 hours post treatment
- Substance P dependent – use NK1 receptor antagonists
What is anticipatory CINV? (1)
Occurs as a conditioned response due to past negative experience (occurs prior to chemo) (lorazepam)
What is breakthrough CINV? (1)
Occurs despite appropriate prophylactic anti-emetics and/or requires rescue agents
Should know the key point (mechanism) in how acute CINV actually occurs
The acute phase emesis is largely initiated by serotonin from enterochromaffin cells located in the intestinal mucosa. Serotonin binds to 5-HT3 receptors located on vagal afferent nerves in the intestinal wall, which send signals via the chemotherapy trigger zone in the area postrema to the vomiting centre in the medulla
What are 2 major factors predicting risk for acute/delayed CINV?
- Treatment related
- Patient related
What are treatment related factors for predicting acute CINV? (3)
- Intrinsic property of drug - emetogenecity
- Dose, route, rate of infusion
- Repeated cycles
What are patient related factors for predicting acute CINV? (2+3)
- Patient characteristics
- Lower alcohol consumption, younger age, female
- History of motion sickness
- History of n/v during pregnancy - Poor control with prior chemotherapy
What are treatment related factors for predicting delayed CINV? (1)
Not well characterized with many chemotherapeutic agents
What are patient related factors for predicting delayed CINV? (2+2)
- Patient characteristics
- Low alcohol consumption, younger age, female
- History of motion sickness - Poor control of acute CINV
What is the 4 drug backbone (acute setting) for high emetic risk regimens? (antiemetics)
- 5-HT3 antagonist
- NK1 antagonist
- Corticosteroids
- Olanzapine
What are the 3 first generation serotonin receptor antagonists (anti-emetic)
- Ondansetron
- Dolasetron
- Granisetron
When are first generation serotonin receptor antagonists most effective (anti-emetics)?
These agents have been shown to be effective in the first 24 hours postchemotherapy (acute phase), but not on days 2 to 5 postchemotherapy (delayed phase)
What is the second generation serotonin receptor antagonist drug?
Palonosetron
What are 2 neurokinin 1 (NK-1) receptor antagonist drugs?
- Fosaprepitant (IV)
- Akynzeo - is NK-1 combined with palonosetron
What 2 drugs are present in Akynzeo?
Netupitant/palonosetron
What are 2 indications of Akynzeo?
- The prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC)
- The prevention of acute nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) that is uncontrolled by a 5-HT3 receptor antagonist alone
What is the MOA of Akynzeo? (3)
- Akynzeo®, a fixed-dose combination of netupitant and palonosetron, has a dual mode of action targeting both the 5-HT3 and NK1 receptor neuropathways
- Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for 5-HT3 receptors
- Netupitant is a selective NK1 receptor antagonist that inhibits substance P-mediated responses, as shown in in vivo and in vitro studies
Carboplatin AUC >_ is when we consider it to be high
4
Need to know the highly emetogenic chemotherapy (HEC), including cisplatin-based regimens anti-emetic treatment, with dosing, days 1-4
Day 1:
- Akynzeo 1 capsule, ~1 hour prior to the start of each chemotherapy cycle
- Dexamethasone 12mg
Day 2:
- DEX 8mg
Day 3:
- DEX 8mg
Day 4:
- DEX 8mg